Companies › Adlai Nortye Biopharma
4 active drug programs in 4 registered trials: 4 Phase 1; Oncology; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| AN4005 | – | Phase 1 | Advanced Solid Tumor | Nov 2026 |
| AN8025 Multifunctional antibody fusion protein | – | Phase 1 | Advanced Solid Tumor (Phase 1) | Jul 2027 |
| AN9025 Pan-RAS inhibitor that binds cyclophilin A (CypA) and forms a tri-complex with GTP-bound R | KRAS, NRAS, HRAS | Phase 1 | Solid Tumors (Phase 1) | Jan 2028 |
| AN4035 CEACAM5-targeting antibody-drug conjugate (ADC) delivering a pan-RAS(ON) inhibitor payload | CEACAM5, KRAS, NRAS, HRAS | Phase 1 | Solid Tumor (Phase I) | Dec 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT04999384 | AN4005 | Phase 1 | Advanced Solid Tumor | Oncology | Nov 2026 |
| NCT07639047 | AN8025 | Phase 1 | Advanced Solid Tumor (Phase 1) | Oncology | Jul 2027 |
| NCT07252479 | AN9025 | Phase 1 | Solid Tumors (Phase 1) | Oncology | Jan 2028 |
| NCT07686445 | AN4035 | Phase 1 | Solid Tumor (Phase I) | Oncology | Dec 2028 |
Cash of $61m on 2024-12-31; operating cash outflow about $52m a year; runway about 14 months at that burn, to Mar 2026
Held by 11 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.